Market closedNon-fractional
Foghorn Therapeutics/FHTX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About Foghorn Therapeutics
Foghorn Therapeutics Inc is engaged in the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Its proprietary Gene Traffic Control platform gives an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing it to identify, validate, and potentially drug targets within the system. The company is developing FHD-286, a selective, allosteric ATPase inhibitor, and FHD-609, a protein degrader, to treat hematologic cancers and solid tumors.
Ticker
FHTX
Sector
Healthcare
Trading on
NASDAQ
Industry
Biotechnology
Headquarters
Cambridge, United States
Employees
116
Website
foghorntx.com
FHTX Metrics
BasicAdvanced
$361M
Market cap
-
P/E ratio
-$2.21
EPS
3.15
Beta
-
Dividend rate
Price and volume
Market cap
$361M
Beta
3.15
Financial strength
Current ratio
4.063
Quick ratio
3.969
Long term debt to equity
-35.196
Total debt to equity
-44.087
Management effectiveness
Return on assets (TTM)
-20.46%
Return on equity (TTM)
152.29%
Valuation
Price to revenue (TTM)
8.104
Price to book
-2.87
Price to tangible book (TTM)
-2.87
Price to free cash flow (TTM)
-2.349
Growth
Revenue change (TTM)
64.41%
Earnings per share change (TTM)
-18.18%
3-year revenue growth (CAGR)
261.75%
3-year earnings per share growth (CAGR)
-18.69%
What the Analysts think about FHTX
Analyst Ratings
Majority rating from 5 analysts.
FHTX Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$5M
-12.28%
Net income
-$25M
3.73%
Profit margin
-500.00%
18.26%
FHTX Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.70
-$0.34
-$0.57
-$0.59
-
Expected
-$0.74
-$0.75
-$0.76
-$0.63
-$0.66
Surprise
-4.76%
-54.65%
-25.31%
-6.87%
-
FHTX News
AllArticlesVideos
Foghorn Therapeutics to Participate in Upcoming Investor Conferences in June
GlobeNewsWire·2 months ago
Foghorn Therapeutics Raises Approximately $110 Million Through Registered Direct Offering to Advance Pipeline
GlobeNewsWire·2 months ago
Foghorn Announces Pricing of Registered Direct Offering of Common Stock and Pre-Funded Warrants
GlobeNewsWire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Foghorn Therapeutics stock?
Foghorn Therapeutics (FHTX) has a market cap of $361M as of July 26, 2024.
What is the P/E ratio for Foghorn Therapeutics stock?
The price to earnings (P/E) ratio for Foghorn Therapeutics (FHTX) stock is 0 as of July 26, 2024.
Does Foghorn Therapeutics stock pay dividends?
No, Foghorn Therapeutics (FHTX) stock does not pay dividends to its shareholders as of July 26, 2024.
When is the next Foghorn Therapeutics dividend payment date?
Foghorn Therapeutics (FHTX) stock does not pay dividends to its shareholders.
What is the beta indicator for Foghorn Therapeutics?
Foghorn Therapeutics (FHTX) has a beta rating of 3.15. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.
Buy or sell Foghorn Therapeutics stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.